EPDR1

Across TCGA pan-cancer cohorts, EPDR1 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated EPDR1 data layer compared with 25 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher EPDR1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated EPDR1 expression acts as an unfavorable survival marker, although some lineages such as BLCA show a favorable association.

LUAD, SCLC, and UCEC are the cancer types where EPDR1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	All	0.098	0.791	<.001	18	view →
SCLC	OS	Median	All	0.082	0.653	.002	9	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
BLCA	OS	Median	II,III,IV	1.000	0.412	.045	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

EPDR1–LUAD (DFS)

Open the LUAD breakdown →